DataSheet_1_Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.docx

In this study, a bibliometric analysis was carried out to identify the most influential clinical studies and research trends on anti-programmed cell death 1/programmed cell death 1 ligand 1 (anti-PD1/PDL1) immunotherapy. On January 1, 2022, we used Web of Science to identify the 100 most frequently cited papers on clinical studies investigating anti-PD1/PDL1 immunotherapy, and extracted the following data: publication year, source title, country/region, institution, and the total number of citations. The research design and area were classified independently by the authors. Subsequently, we carried out a bibliometric analysis to determine the trends and identify the major journals on anti-PD1/PDL1 immunotherapy. The authors analyzed the current research hotspots based on papers published in major journals from 2020 to 2021. These 100 papers were cited a total of 138,840 times, and the median number of citations was 899.5 (range: 341–7,983). “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer” by Topalian et al. had the highest number of citations (7,983 times). New England Journal of Medicine had the highest number of top-cited papers (40 papers), average citations per paper (1,558.3 citations), and rate of top-cited papers (65.6%). Authors from the USA contributed most of the papers (76 papers). Lung cancer (30 papers, 46,422 citations) and melanoma (20 papers, 30,881 citations) were the most cited research areas. In summary, anti-PD1/PDL1 has become standard treatment for various cancer, while adjuvant anti-PD1/PDL1 therapy is currently a research hotspot. New England Journal of Medicine was identified as the most influential journal in this area. Non-small cell lung cancer and melanoma are the most well-studied cancers, while nivolumab and pembrolizumab are the most commonly investigated anti-PD1/PDL1 antibodies. Further studies are warranted to identify effective predictive biomarkers or models, clarify the molecular mechanism of combined therapy, and establish optimal therapeutic strategies. This study may assist researchers in obtaining a comprehensive impression of the landscape and current trends in anti-PD1/PDL1 immunotherapy and gain inspiration to conduct further studies.

本研究采用文献计量分析方法，旨在明确抗程序性死亡蛋白1/程序性死亡蛋白配体1（anti-PD1/PDL1）免疫疗法领域最具影响力的临床研究及研究趋势。2022年1月1日，我们通过Web of Science数据库检索得到抗PD1/PDL1免疫疗法临床研究领域被引频次最高的100篇论文，并提取如下数据：发表年份、来源期刊名称、所属国家/地区、研究机构以及总被引次数。研究设计与研究领域由作者独立完成分类。随后，我们开展文献计量分析，以明确该领域的研究趋势，并梳理该领域的核心期刊。作者基于2020至2021年发表于核心期刊的论文，分析了当前的研究热点。上述100篇论文总被引次数达138840次，中位被引频次为899.5次（区间：341~7983次）。Topalian等人发表的《癌症中抗PD-1抗体的安全性、活性及免疫相关性》一文被引次数最高，达7983次。《新英格兰医学杂志》（New England Journal of Medicine）的高被引论文数量（40篇）、篇均被引次数（1558.3次）及高被引论文占比（65.6%）均位居首位。美国作者完成的论文数量最多，共计76篇。肺癌（30篇论文，总被引46422次）与黑色素瘤（20篇论文，总被引30881次）是被引频次最高的研究方向。综上，抗PD1/PDL1免疫疗法已成为多种恶性肿瘤的标准治疗方案，而辅助性抗PD1/PDL1免疫疗法则是当前的研究热点。《新英格兰医学杂志》被认定为该领域最具影响力的期刊。非小细胞肺癌与黑色素瘤是研究最为深入的癌种，而纳武利尤单抗（nivolumab）与帕博利珠单抗（pembrolizumab）则是最常被研究的抗PD1/PDL1抗体药物。未来仍需开展进一步研究，以发掘有效的预测性生物标志物或预测模型，阐明联合治疗的分子机制，并确立最优治疗策略。本研究可帮助研究人员全面了解抗PD1/PDL1免疫疗法的研究格局与当前趋势，为后续研究提供灵感与参考。